These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33992916)

  • 1. Immune reconstitution therapy in NMOSD.
    Brod SA
    Mult Scler Relat Disord; 2021 Jul; 52():102971. PubMed ID: 33992916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.
    Brod SA
    Mult Scler Relat Disord; 2020 Nov; 46():102538. PubMed ID: 33059216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial].
    Fujihara K; Sato H
    Brain Nerve; 2024 Oct; 76(10):1153-1160. PubMed ID: 39370840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Nabizadeh F; Masrouri S; Sharifkazemi H; Azami M; Nikfarjam M; Moghadasi AN
    J Clin Neurosci; 2022 Nov; 105():37-44. PubMed ID: 36075186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
    Meher BR; Mohanty RR; Dash A
    Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
    Paul F; Marignier R; Palace J; Arrambide G; Asgari N; Bennett JL; Cree BAC; De Sèze J; Fujihara K; Kim HJ; Hornby R; Huda S; Kissani N; Kleiter I; Kuwabara S; Lana-Peixoto M; Law L; Leite MI; Pandit L; Pittock SJ; Quan C; Ramanathan S; Rotstein D; Saiz A; Sato DK; Vaknin-Dembinsky A
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37258412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis Optica Spectrum Disorders.
    Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
    Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
    Giglhuber K; Berthele A
    Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.